Abstract:Objective:To explore the association of molecular subtypes with local recurrence, distant metastasis and prognosis in breast cancer patients undergoing adjuvant therapy after modified radical mastectomy as well as its significance.Methods:The clinical data of 108 patients with breast cancer undergoing adjuvant therapy after modified radical operation in the First Affiliated Hospital of Xi'an Jiaotong University from March 2002 to March 2012 were retrospectively analyzed. According to the expressions of estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor-2 (HER2), patients with breast cancer were divided into 4 molecular subtypes, including Luminal A, Luminal B, HER2-positive and triple-negative. The relationship between clinicopathological factors and molecular subtypes was analyzed, and the local recurrence rate and distant metastasis rate of breast cancer patients with various molecular subtypes were compared. Kaplan-Meier method and log-rank test were used to make single factor analysis of survival. Cox proportional hazard model was used to make multi-factor survival analysis.Results:Among 108 patients, 41 cases were Luminal A, 40 cases were Luminal B, 17 cases were HER2-positive and 10 cases were triple-negative. The differences in compositions of patients with age, tumor size, pathological type, lymph node metastasis, American Joint Committee on Cancer (AJCC) staging, vascular tumor thrombus, resection margin, and chemotherapy cycle number among groups with 4 molecular subtypes were not statistically significant (all P > 0.05), while the difference in compositions of patients receiving endocrine therapy was statistically significant ( P < 0.01). The local recurrence rate of patients with Luminal A, Luminal B, HER2 positive and triple-negative was 14.6% (6/41),15.0% (6/40), 11.8% (2/17), 10.0% (1/10), respectively, and the difference was not statistically significant ( P > 0.05). The distant metastasis rate of patients with HER2-positive and triple-negative was 35.3% (6/17) and 40% (4/10), respectively, which was higher than that of patients with Luminal A [24.4% (10/41)] and Luminal B [22.5% (9/40)], but there was no statistically significant difference among the four types ( P > 0.05). Kaplan-Meier analysis showed there was no statistical difference in progression-free survival of patients with Luminal A, Luminal B, HER2-positive and triple-negative ( P > 0.05), while there was a statistical difference in the overall survival (OS) ( P = 0.047), and the OS of triple-negative patients was the worst, meanwhile AJCC staging, lymph node metastasis and endocrine therapy were associated with the OS (all P < 0.05). Multi-factor Cox proportional hazard model analysis showed that lymph node metastasis ( OR = 4.481, 95% CI 1.377-14.580, P = 0.013) and endocrine therapy ( OR = 0.165, 95% CI 0.034-0.800, P = 0.025) were independent prognostic factors affecting OS. Conclusions:There is no statistically significant difference in local recurrence rate for breast cancer patients with different molecular types undergoing adjuvant therapy after modified radical mastectomy. Breast cancer patients with Luminal have better OS, while those with triple-negative have the worst OS. Molecular subtypes may have an important significance for the treatment choice and prognosis judgement of breast cancer.

Breast Cancer Subtypes and Survival in Chinese Women with Operable Primary Breast Cancer

Distinct Distribution and Prognostic Significance of Molecular Subtypes of Breast Cancer in Chinese Women: a Population-Based Cohort Study

Clinical Characteristics and Prognosis of Different Subtypes of Breast Cancer

Characteristics and prognosis for molecular breast cancer subtypes in Chinese women

Triple-negative Breast Cancer Types Exhibit a Distinct Poor Clinical Characteristic in Lymph Node-Negative Chinese Patients

Luminal B Subtype: a Key Factor for the Worse Prognosis of Young Breast Cancer Patients in China.

Biological subtype predicts locoregional recurrence after postmastectomy radiotherapy in Chinese breast cancer patients.

The characteristics of breast cancer subtypes: implications for treatment guidelines and individualized treatment strategies in China.

Molecular Subtype Can Predict the Response and Outcome of Chinese Locally Advanced Breast Cancer Patients Treated with Preoperative Therapy

Combination Impact Of Axillary Lymph Node Status And Biological Subtypes On Prognosis And Breast Conserving Surgery In Locally-Invasive Breast Cancer: A Real-World Study Of A Chinese Population

Molecular Subtype Approximated by Quantitative Estrogen Receptor, Progesterone Receptor and Her2 Can Predict the Prognosis of Breast Cancer

Clinical significance of four subtypes of breast cancer

Clinical Characteristics and Survival Analysis of Breast Cancer Molecular Subtypes with Hepatic Metastases

Clinicopathologic Characteristics and Prognosis in Young Chinese Women with Breast Cancer

The Diverse Distribution Of Risk Factors Between Breast Cancer Subtypes Of Er, Pr And Her2: A 10-Year Retrospective Multi-Center Study In China

[Relationship Between Breast Cancer Molecular Subtypes with Clinicopathological Characteristics and Prognosis].

Pathological features and prognosis of different molecular subtypes of breast cancer

Clinical characteristics and prognosis of different subtypes ofbreast cancer with bone metastasis

Clinicopathological features of the triple-negative tumors in Chinese breast cancer patients

Characteristics and prognostic values of traditional pathological parameters and advanced molecular subtypes in women in Beijing with operable breast cancer: a retrospective analysis.

Association of molecular subtypes with local recurrence, distant metastasis and prognosis in breast cancer patients after modified radical mastectomy